Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Mutation testing for non-small-cell lung cancer].
Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L. Brustugun OT, et al. Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):952-5. doi: 10.4045/tidsskr.11.1017. Tidsskr Nor Laegeforen. 2012. PMID: 22562326 Free article. Norwegian.
Clinical significance of disseminated tumour cells in non-small cell lung cancer.
Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K. Rud AK, et al. Among authors: brustugun ot. Br J Cancer. 2013 Sep 3;109(5):1264-70. doi: 10.1038/bjc.2013.450. Epub 2013 Aug 13. Br J Cancer. 2013. PMID: 23942067 Free PMC article.
Osteopontin is a prognostic biomarker in non-small cell lung cancer.
Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM. Rud AK, et al. Among authors: brustugun ot. BMC Cancer. 2013 Nov 11;13:540. doi: 10.1186/1471-2407-13-540. BMC Cancer. 2013. PMID: 24215488 Free PMC article.
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H. Grønberg BH, et al. Among authors: brustugun ot. J Thorac Oncol. 2013 Oct;8(10):1255-64. doi: 10.1097/JTO.0b013e3182a406a3. J Thorac Oncol. 2013. PMID: 24457236 Free article. Clinical Trial.
BRAF-mutations in non-small cell lung cancer.
Brustugun OT, Khattak AM, Trømborg AK, Beigi M, Beiske K, Lund-Iversen M, Helland Å. Brustugun OT, et al. Lung Cancer. 2014 Apr;84(1):36-8. doi: 10.1016/j.lungcan.2014.01.023. Epub 2014 Feb 3. Lung Cancer. 2014. PMID: 24552757
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.
Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT. Donnem T, et al. Among authors: brustugun ot. Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13. Clin Cancer Res. 2015. PMID: 25680376
144 results